CompletedNot Applicable

Role of ARMA in Selective Subset of Refractory GERD Patients.

India50 participantsStarted 2023-03-30

Plain-language summary

To study the role of a novel endoscopic treatment technique (ARMA) in GERD patients who doesn't respond to PPI therapy (Proton Pump Inhibitor).

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Normal Upper Gastrointestinal endoscopy And * 24 hour pH Impedance: AET \< 6%, More than 80 refluxes * Patients who are willing to give consent for the procedure Exclusion Criteria: * Large Hiatal hernia \>3cm * Lower esophageal sphincter (LES) pressure \>15 mm Hg * Paraesophageal hernia * GE flap valve grade IV (Hill's classification) * Barretts esophagus * Esophageal dysmotility * ASA physical status \>II * Previous esophageal or gastric surgery * Pregnancy

What they're measuring

Improvement in Gastro esophageal reflux disease symptoms by more than 50% from baseline at 3 months.

Timeframe: One Year

Trial details

NCT IDNCT05899491

SponsorAsian Institute of Gastroenterology, India

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-30

View on ClinicalTrials.gov More GERD trials